COMPANY PROFILE

Quench Bio

Explore full profile

Quench Bio is a biotechnology company leveraging new insights into gasdermin biology

Cambridge, United StatesFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2020

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Quench Bio

Quench Bio is a biotechnology company focused on developing novel therapies for severe inflammatory diseases by targeting gasdermins, key proteins involved in inflammatory cell death. The company operates in the biopharmaceutical sector, serving patients with unmet medical needs in inflammation-related conditions. Quench Bio's business model revolves around the discovery and development of small molecule inhibitors that modulate the activity of gasdermins, aiming to create transformational treatments. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The company leverages cutting-edge molecular biology research and has assembled a team of experienced biopharma leaders and scientists, guided by world-class scientific advisors and a seasoned board of directors. Quench Bio is strategically positioned to bring impactful therapies to market, addressing critical gaps in the treatment of inflammatory diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Closed
Founded: 2018
Headquarters: Cambridge, United States
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Jan 2020	$50M	$200M	Arix Bioscience · RA Capital Management · Atlas Venture · Abbvie Biotech Ventures	—
SPINOUTOther financing	Jan 2018	$0	—	Max Planck Innovation · Max Planck Society	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Quench Bio website traffic

Latest recorded traffic for Quench Bio is 230 monthly website visits, up 91.7% over the last three months.

Latest monthly visits230 3-month web change+91.7%

Monthly website visitsJan 2020–Apr 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational	15	$25M	$100M
DPDISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds	Cologne, Germany	Operational
VIVilyaDeveloping a novel class of drugs that precisely target the biology of disease	Seattle, United States	Operational
STSeismic TherapeuticThe Machine Learning Immunology Company	Cambridge, United States	Operational
HOHolloidProvides real-time multi-dimensional data on colloids, based on 3D imaging, with the throughput of cytometry	Vienna, Austria	Operational
OBOctarine BioHarnessing the powers of synthetic biology to develop rare and superior cannabinoids and psychedelic derivatives	Copenhagen, Denmark	Operational
CECellSpringThe Next Level in 3D Cell Culture	Zurich, Switzerland	Operational
TSTheranosis Life SciencesA fully functioning cell culture facility and molecular biology setup	Hyderabad, India	Operational